STTK CTO exercises warrants, gets 5,122 shares
Shattuck Labs, Inc. Chief Technical Officer Abhinav A. Shukla reported routine equity transactions involving company stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Shattuck Labs, Inc. Chief Technical Officer Abhinav A. Shukla reported routine equity transactions involving company stock. He received a grant or award of 5,122 shares of common stock at $1.0846 per share, increasing his direct holdings to 86,380 shares.
On the same date, he exercised warrants covering 5,122 shares of common stock at an exercise price of $1.0846 per share, eliminating this warrant position. Footnotes explain these warrants and shares stemmed from a prior private placement that included common stock and accompanying warrants issued under a securities purchase agreement.
Insider Trade Summary
5,122 shares exercised/converted
Exercise
2 txns
Insider
Shukla Abhinav A.
Role
Chief Technical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Warrants (Right to Buy) | 5,122 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 5,122 | $1.0846 | $6K |
Holdings After Transaction:
Warrants (Right to Buy) — 0 contracts (Direct);
Common Stock — 86,380 shares (Direct)
Footnotes (2)
- F1. On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 5,122 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 5,122 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677.
- F2. The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.
Key Figures
Common stock grant: 5,122 shares
Grant price: $1.0846 per share
Warrants exercised: 5,122 warrants
+4 more
7 metrics
Common stock grant
5,122 shares
Grant or award of common stock on May 21, 2026
Grant price
$1.0846 per share
Price for 5,122 granted common shares
Warrants exercised
5,122 warrants
Exercise of warrants into 5,122 common shares
Warrant exercise price
$1.0846 per share
Exercise or conversion price for warrants
Shares owned after
86,380 shares
Direct common stock holdings following transactions
Private placement unit price
$0.8677 per unit
Combined price per common share and accompanying warrant
Underlying warrant shares
5,122 shares
Common shares underlying the exercised warrants
Key Terms
securities purchase agreement, private placement, accompanying warrants, Phase 1 clinical trial, +1 more
5 terms
securities purchase agreement financial
"the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
private placement financial
"the Issuer in a private placement, which closed on August 25, 2025, issued and sold"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
accompanying warrants financial
"issued and sold to the Reporting Person 5,122 shares of the Issuer's common stock and accompanying warrants"
Securities called accompanying warrants are options issued together with another financing instrument—often bonds or preferred shares—that give the holder the right to buy common stock at a set price for a limited time. Think of them like detachable coupons included with a loan that can be redeemed later for stock; they matter to investors because they can dilute existing ownership if exercised and add potential upside tied to the issuer’s future share price.
Phase 1 clinical trial technical
"the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data"
A phase 1 clinical trial is the first stage of testing a new drug or treatment in people, typically involving a small group to assess safety, how the body handles the treatment, and appropriate dosing. For investors, phase 1 results are an early risk check — like a test drive that can reveal fatal flaws or promising signals — and they often cause big changes in a drug’s perceived value and the company’s prospects.
Phase 2 clinical trial(s) technical
"and the design of the planned Phase 2 clinical trial(s) have been announced publicly"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Were the STTK transactions open-market buys or sells?
No open-market buys or sells were reported. The filing shows a grant or award of 5,122 common shares and the exercise of warrants for 5,122 underlying shares. Both are classified as acquisition and derivative exercise events, not open-market purchases or sales of existing stock.
What does the Form 4 reveal about STTK’s SL-325 clinical trial warrants?
Footnotes state the warrants are exercisable until 30 days after data from single and multiple ascending dose portions of Shattuck’s Phase 1 SL-325 trial, along with Phase 2 design details, have been publicly announced. This links warrant timing to clinical and safety data milestones.
AI-generated analysis. How Rhea-AI works. Not financial advice.
